The SLIM study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia

Abstract

Background-The combination of niacin and statin has proven value in hyperlipidemia management and heart disease prevention. However, the efficacy of the non-prescription time-release niacin, Slo-Niacin®, is little studied alone and not at all with atorvastatin. We gave Slo-Niacin® and atorvastatin, singly and together to determine efficacy on the combined abnormalities of triglyceride, LDL and HDL.

Metabolomic tissue signature in human non‐alcoholic fatty liver disease identifies protective candidate metabolites

“…Transaminase elevations are a typical concern in drug management of hyperlipidemia and have thus been measured in several clinical trials for drug safety. Here, conflicting results, with studies reporting decreasing as well as increasing transaminase levels, depending on the niacin formulation utilized have been reported. Nicotinic acid is associated with side effects – most notably flushing – that have slowed down broad clinical application .…”

Efficacy and Safety Evaluation of a Large Niacin Therapeutic Interchange Program

“…20 The manufacture of Slo-Niacin began in 1988 and has occurred in a US facility held to all regulatory requirements for pharmaceutical and dietary supplement product current Good Manufacturing Practice. 21, 22 The SA properties of Slo-Niacin result from a patented formulation consisting of hypromellose and hydrogenated vegetable oil; the remaining excipient ingredients include glycerol behenate, magnesium stearate, and silicon dioxide. 20 While the tablet composition of Slo-Niacin appears to be somewhat similar to that of Niaspan, Slo-Niacin has a slightly more rapid rate of dissolution (116.7 mg/h vs 90.3-100 mg/h, respectively).…”

Niacin: Does It affect 8-hydroxy-2-deoxyguanosine levels of the patients having low HDL cholesterol levels?

“…The routine use of early preparations of niacin was limited by side effect profile. Niacin has been superseded in recent years with the advent of newer lipid-modulating interventions [3,4,8]. However, whether niacin itself is used routinely in the future will depend on the outcomes of two large outcome trial (AIM-HIGH and HPS2-THRIVE) [9,10].…”